This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Radiopharmaceuticals & Imaging
March 14, 2023
Digital Conference8:00AM EDT // 12:00PM GMT // 1:00PM CET
Menu
Key Sessions
Thom Tulip
Expansion of Radiopharmaceutical Theranostics for the Treatment, Monitoring, and Imaging of Several Oncological Indications
Radiopharm Theranostics, USA
Michael Schultz
Peptide Based Pb-203/Pb-212 Image-Guided Alpha-Particle Receptor-Targeted Radionuclide Therapy for Cancer: Matching up Physics, Biology, and Isotope Supply
Perspective Therapeutics, USA
keyboard_arrow_right

Radiopharmaceuticals & Imaging - ET (Eastern Time, GMT-05:00)

search

Radiopharmaceuticals & Imaging - ET (Eastern Time, GMT-05:00)

search
Showing 1 of 1 Streams
8:00am - 8:05am
Welcoming Remarks
  • Lottie Leinfellner - Digital Events Conference Producer, Informa Connect, UK
8:05am - 8:35am
Expansion of Radiopharmaceutical Theranostics for the Treatment, Monitoring, and Imaging of Several Oncological Indications
  • Thom Tulip - Chief Business Officer, Radiopharm Theranostics, USA
8:35am - 9:05am
Novel Treatment for the Selective Targeting of Metastatic HER2-Positive Cancer
  • Ruth Devenyns - CEO, Precirix, Belgium
9:05am - 9:35am
Peptide Based Pb-203/Pb-212 Image-Guided Alpha-Particle Receptor-Targeted Radionuclide Therapy for Cancer: Matching up Physics, Biology, and Isotope Supply
  • Michael Schultz - Chief Science Officer, Perspective Therapeutics, USA
9:35am - 10:05am
Coffee Break & Networking Opportunities on the ConnectMe Platform
10:05am - 10:35am
The Affibody® Technology: How ABY-025 Can Improve Diagnostics and Enable Precision Medicine for HER2 Cancers
  • Guido Wuerth - Head of Global Programs, Affibody AB, Germany
10:35am - 11:05am
PreTarg-it®: A Modular Platform Utilizing Bispecific Antibodies for Optimized Biodelivery of Payloads
  • Alejandro Puchol - Scientist, OncoOne, Austria
11:05am - 11:35am
Fibroblast Activation Protein (FAP) Inhibitors as Biomarkers in Oncology, Fibrosis, and Cardiovascular Disease
  • Sherly Mosessian - Chief Scientific Officer, SOFIE, USA
11:35am - 12:05pm
Development of Pb212 -Labelled Radiotherapeutics for Targeted Alpha-Emitter Therapy
  • Izabela Tworowska - Chief Scientific Officer, RADIOMEDIX, Inc., USA
12:05pm - 12:35pm
Coffee Break & Networking Opportunities on the ConnectMe Platform
12:35pm - 1:05pm
Industry and Academic Relationships from the Academic Perspective
  • Michael L. Nickels - Director, Cyclotron Facility Mallinckrodt Institute of Radiology, Washington University School of Medicine, USA
1:05pm - 1:35pm
Building Capacity and Knowledge for Effective Radioisotope Production and Successful Radiopharmaceutical Programs
  • Aruna Korde - Radiopharmaceutical Scientist, Radioisotope Products and Radiation Technology Section| Division of Physical and Chemical Sciences, International Atomic Energy Association, Austria
1:35pm - 2:05pm
Building and Fortifying a Reliable Supply Chain for Radiopharmaceuticals
  • Shaemus Gleason - Executive Vice President, Clarity Pharmaceuticals, USA
2:05pm - 2:10pm
End of Day/ Networking on the Platform
Choose Day